Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks

Cancer Letters

Volumn 369, Issue 2, 2015, Pages 416-426

  Achyut, B R ^a   Shankar, Adarsh ^a   Iskander, A S M ^a   Ara, Roxan ^a   Angara, Kartik ^a   Zeng, Peng ^a   Knight, Robert A ^b   Scicli, Alfonso G ^b   Arbab, Ali S ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Bone marrow; Glioblastoma; Resistance; Tumor angiogenesis; Tumor microenvironment; VEGF

Indexed keywords

CD11B ANTIGEN; CD133 ANTIGEN; CD34 ANTIGEN; CD68 ANTIGEN; VATALANIB; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; GLIOBLASTOMA; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN TUMOR; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MICE; MYELOID CELLS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84945301921     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.004     Document Type: Article

References (81)

1. Olar A., Aldape K.D. Using the molecular classification of glioblastoma to inform personalized treatment. J. Pathol 2014, 232:165-177.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med 2005, 352:987-996.
3. Brat D.J., Van Meir E.G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. Invest 2004, 84:397-405.
4. Jain R.K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014, 26:605-622.
5. Zhao Y., Adjei A.A. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 2015, 20:660-673.
6. Arbab A.S. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol. Histopathol 2012, 27:549-557.
7. Kumar S., Arbab A.S. Neovascularization in glioblastoma: current pitfall in anti-angiogenic therapy. Zhong Liu Za Zhi 2013, 1:16-19.
8. Scarlett C.J. Contribution of bone marrow derived cells to the pancreatic tumor microenvironment. Frontiers in physiology 2013, 4:56.
9. Aghi M., Cohen K.S., Klein R.J., Scadden D.T., Chiocca E.A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006, 66:9054-9064.
10. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med 2004, 10:858-864.
11. De Falco E., Porcelli D., Torella A.R., Straino S., Iachininoto M.G., Orlandi A., et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004, 104:3472-3482.
12. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
13. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
14. Huang Y., Hoffman C., Rajappa P., Kim J.H., Hu W., Huse J., et al. Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res 2014, 74:1011-1021.
15. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
16. Ahn G.O., Brown J.M. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 2009, 12:159-164.
17. Deak E., Gottig S., Ruster B., Paunescu V., Seifried E., Gille J., et al. Bone marrow derived cells in the tumour microenvironment contain cells with primitive haematopoietic phenotype. J. Cell. Mol. Med 2010, 14:1946-1952.
18. Shinde Patil V.R., Friedrich E.B., Wolley A.E., Gerszten R.E., Allport J.R., Weissleder R. Bone marrow-derived lin(-)c-kit(+)Sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. Neoplasia 2005, 7:234-240.
19. Seandel M., Butler J., Lyden D., Rafii S. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell 2008, 13:181-183.
20. Achyut B.R. Impact of microenvironment in therapy-induced neovascularization of glioblastoma. Biochem. Physiol 2013, 2:e121.
21. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med 2013, 19:1114-1123.
22. Dondossola E., Rangel R., Guzman-Rojas L., Barbu E.M., Hosoya H., St John L.S., et al. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:20717-20722.
23. Lu-Emerson C., Snuderl M., Kirkpatrick N.D., Goveia J., Davidson C., Huang Y., et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncol 2013, 15:1079-1087.
24. Phan V.T., Wu X., Cheng J.H., Sheng R.X., Chung A.S., Zhuang G., et al. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:6079-6084.
25. Seton-Rogers S. Tumour microenvironment: means of resistance. Nat. Rev. Cancer 2013, 13:607.
26. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6742-6747.
27. Achyut B.R., Arbab A.S. Myeloid derived suppressor cells: fuel the fire. Biochem. Physiol 2014, 3:e123.
28. Lu R., Kujawski M., Pan H., Shively J.E. Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. Cancer Res 2012, 72:2239-2250.
29. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
30. Shojaei F., Zhong C., Wu X., Yu L., Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008, 18:372-378.
31. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
32. Gomez Perdiguero E., Klapproth K., Schulz C., Busch K., Azzoni E., Crozet L., et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015, 518:547-551.
33. Wang S.C., Hong J.H., Hsueh C., Chiang C.S. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab. Invest 2012, 92:151-162.
34. Piao Y., Liang J., Holmes L., Zurita A.J., Henry V., Heymach J.V., et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncol 2012, 14:1379-1392.
35. Galdiero M.R., Bonavita E., Barajon I., Garlanda C., Mantovani A., Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013, 218:1402-1410.
36. Hussain S.F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncol 2006, 8:261-279.
37. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42:717-727.
38. Wesolowski R., Markowitz J., Carson W.E. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J. Immunother. Cancer 2013, 1:10.
39. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med 2001, 193:727-740.
40. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
41. MacDonald K.P., Rowe V., Bofinger H.M., Thomas R., Sasmono T., Hume D.A., et al. The colony-stimulating factor 1 receptor is expressed on dendritic cells during differentiation and regulates their expansion. J. Immunol 2005, 175:1399-1405.
42. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
43. Xu J., Escamilla J., Mok S., David J., Priceman S., West B., et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013, 73:2782-2794.
44. Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol 2008, 8:533-544.
45. Hume D.A., MacDonald K.P. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012, 119:1810-1820.
46. Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471.
47. Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014, 74:5057-5069.
48. Ali M.M., Kumar S., Shankar A., Varma N.R., Iskander A.S., Janic B., et al. Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. Transl. Oncol 2013, 6:660-669.
49. Yuen D.A., Stead B.E., Zhang Y., White K.E., Kabir M.G., Thai K., et al. eNOS deficiency predisposes podocytes to injury in diabetes. J. Am. Soc. Nephrol 2012, 23:1810-1823.
50. Conway J.G., McDonald B., Parham J., Keith B., Rusnak D.W., Shaw E., et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:16078-16083.
51. Ding G., Jiang Q., Zhang L., Zhang Z.G., Li L., Knight R.A., et al. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. J. Cereb. Blood Flow Metab 2005, 25:87-97.
52. Ewing J.R., Knight R.A., Nagaraja T.N., Yee J.S., Nagesh V., Whitton P.A., et al. Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening. Magn. Reson. Med 2003, 50:283-292.
53. Nagaraja T.N., Karki K., Ewing J.R., Croxen R.L., Knight R.A. Identification of variations in blood-brain barrier opening after cerebral ischemia by dual contrast-enhanced magnetic resonance imaging and t1sat measurements. Stroke 2008, 39:427-432.
54. Nagaraja T.N., Karki K., Ewing J.R., Divine G.W., Fenstermacher J.D., Patlak C.S., et al. The MRI-measured arterial input function resulting from a bolus injection of Gd-DTPA in a rat model of stroke slightly underestimates that of Gd-[14C]DTPA and marginally overestimates the blood-to-brain influx rate constant determined by Patlak plots. Magn. Reson. Med 2010, 63:1502-1509.
55. Bruno A., Pagani A., Magnani E., Rossi T., Noonan D.M., Cantelmo A.R., et al. Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention. Cancer Treat. Res 2014, 159:401-426.
56. Dietrich J., Norden A.D., Wen P.Y. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr. Opin. Neurol 2008, 21:736-744.
57. Mittal K., Ebos J., Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin. Oncol 2014, 41:235-251.
58. Rahman R., Smith S., Rahman C., Grundy R. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J. Oncol 2010, 2010. 251231.
59. Saharinen P., Eklund L., Pulkki K., Bono P., Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med 2011, 17:347-362.
60. Samples J., Willis M., Klauber-DeMore N. Targeting angiogenesis and the tumor microenvironment. Surg. Oncol. Clin. N. Am 2013, 22:629.
61. Miller K.D., Sweeney C.J., Sledge G.W. Can tumor angiogenesis be inhibited without resistance?. EXS 2005, 95-112.
62. Alizadeh D., Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res 2014, 74:2663-2668.
63. Bruchard M., Ghiringhelli F. Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets. Bull. Cancer 2014, 101:605-607.
64. Highfill S.L., Cui Y., Giles A.J., Smith J.P., Zhang H., Morse E., et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med 2014, 6. 237ra267.
65. Mao Y., Sarhan D., Steven A., Seliger B., Kiessling R., Lundqvist A. Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res 2014, 20(15):4096-4106.
66. Mundy-Bosse B.L., Lesinski G.B., Jaime-Ramirez A.C., Benninger K., Khan M., Kuppusamy P., et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011, 71:5101-5110.
67. Qin H., Lerman B., Sakamaki I., Wei G., Cha S.C., Rao S.S., et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat. Med 2014, 20:676-681.
68. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol 2008, 26:127-132.
69. Yu J., Wang Y., Yan F., Zhang P., Li H., Zhao H., et al. Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol 2014, 193:2574-2586.
70. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med 2013, 19:1264-1272.
71. Annabi B., Rojas-Sutterlin S., Laflamme C., Lachambre M.P., Rolland Y., Sartelet H., et al. Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol. Cancer Res 2008, 6:907-916.
72. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
73. Fan Q., Gu D., Liu H., Yang L., Zhang X., Yoder M.C., et al. Defective TGF-beta signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. Cancer Res 2014, 74:471-483.
74. Guedez L., Jensen-Taubman S., Bourboulia D., Kwityn C.J., Wei B., Caterina J., et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J. Immunother 2012, 35:502-512.
75. Yeo L., Adlard N., Biehl M., Juarez M., Smallie T., Snow M., et al. Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis. Ann. Rheum. Dis 2015, 10.1136/annrheumdis-2014-206921.
76. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71:614-624.
77. Labelle M., Begum S., Hynes R.O. Platelets guide the formation of early metastatic niches. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E3053-E3061.
78. Grepin R., Guyot M., Giuliano S., Boncompagni M., Ambrosetti D., Chamorey E., et al. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res 2014, 74:873-883.
79. Raccosta L., Fontana R., Maggioni D., Lanterna C., Villablanca E.J., Paniccia A., et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J. Exp. Med 2013, 210:1711-1728.
80. Katoh H., Wang D., Daikoku T., Sun H., Dey S.K., Dubois R.N. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013, 24:631-644.
81. Huynh J., Kwa M.Q., Cook A.D., Hamilton J.A., Scholz G.M. CSF-1 receptor signalling from endosomes mediates the sustained activation of Erk1/2 and Akt in macrophages. Cell. Signal 2012, 24:1753-1761.